We must now come to a uniform consensus regarding the descriptions of these risk groups in order to truly determine which treatments have the best oncologic efficacy, while minimizing overtreatment and optimizing patients’ quality of life.
Theodore R. Saitz, MD
Advertisement
Articles by Theodore R. Saitz, MD
Advertisement
Latest Updated Articles
- The Quest for an Evidence-Based Approach to Intermediate-Risk Prostate Cancer
Published: March 15th 2016 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
How Will the Continued Success of ADCs in Breast Cancer Be Propelled in the Future?
2
Trial Assessing Savolitinib/Osimertinib in NSCLC Completes Enrollment
3
Searching for Synergy in Liver-Dominant Neuroendocrine Tumors
4
Neoadjuvant Nivolumab/Ipilimumab Shows Superior EFS in Resectable Melanoma
5
